VIEWPOINT

Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine

Willem Lems 1,2, Maarten Boers 3, Ronald F van Vollenhoven 1, Mike Nurmohamed 1

ABSTRACT

We summarised four pivotal Randomised Controlled Trials (RCTs) with antirheumatic drugs on the secondary prevention of cardiovascular events. The favourable effects of canakinumab and colchicine confirm low-grade inflammation as an independent risk factor for cardiovascular events. While colchicine might be the first drug in the clinic, we expect that this is only the first in a future series of anti-inflammatory drugs used in secondary prevention of cardiovascular events.

Chronic inflammation is a key driver in the development of atherosclerotic cardiovascular disease. Proinflammatory mediators such as TNFα and IL-1β are important in the development of dysfunctional endothelium, the first step of atherogenesis. The next step is subendothelial monocyte infiltration where accumulated LDL cholesterol is oxidised leading to atherosclerotic plaque formation. Plaques rupture or develop superficial erosions, causing thrombosis and cardiovascular events.

The important proinflammatory cytokine IL-1β is generated after proteolytic cleavage of pro-IL-1β by caspase-1 that in turn is activated by the nucleotide-binding oligomerisation domain-containing, leucine-rich repeat-containing and pyrin domain-containing protein 3 (NLRP3) inflammasome. Uric acid crystals as well as cholesterol crystals initiate inflammation by complement activation. C3b then activates macrophages to produce the NLRP3 inflammasome.

Methotrexate (MTX) significantly reduces the cardiovascular disease risk in rheumatoid arthritis (RA) by favourable effects on vascular function and blood pressure. The precise underlying mechanisms are not known but are thought to be related with targeting specific inflammatory pathways, particularly the effects on 5′ adenosine monophosphate-activated protein kinase seem to be pivotal.

Recognition of the important role of inflammation in atherogenesis led to trials, in non-arthritis patients, with several anti-inflammatory drugs, that is, canakinumab, MTX and colchicine, to study their potential for secondary prevention of cardiovascular events in patients with established cardiovascular disease.

Two agents target the IL-1β pathway: Canakinumab, an expensive monoclonal antibody, directly inhibits this cytokine; in Europe, it is approved for patients with refractory gout, cryopyrin-associated periodic fever syndromes and Still’s disease. Colchicine is a very old and cheap drug that decreases production of IL-1β and other pro-inflammatory cytokines through inhibition of the formation of the NLPR3 inflammasome. Recently, four pivotal RCT’s with these two agents have been published.

The first study (from 2017) compared three different dosages of canakinumab (50 mg, 150 mg and 300 mg given subcutaneously) versus placebo in 10,061 patients with a history of myocardial infarction and a high-sensitive C reactive protein level of ≥2 mg/L. The primary endpoint was a composite index of non-fatal myocardial infarction, non-fatal stroke and cardiovascular death: after a mean follow-up of 3.7 years, a statistically significant decrease was found in the 150 mg group (HR 0.85, with 95% CI: 0.74 to 0.98, p=0.021) and in the 300 mg group (HR 0.86, 95% CI: 0.75 to 0.99, p=0.031). Thus, this landmark study demonstrated for the first time that an anti-inflammatory drug could reduce the occurrence of cardiovascular events in patients with a previous myocardial infarction. However, the higher incidence of fatal infections and the (current) prohibitively high drug costs.
disqualifies this drug for widespread use in secondary cardiovascular prevention.

Therefore, the Cardiovascular Inflammation Reduction Trial (CIRT) study from 2019 on the effects of MTX for the secondary prevention of atherosclerotic events in patients with previous myocardial infarction or multivessel coronary disease is of interest. MTX is an inexpensive antirheumatic drug, widely recommended as first-line choice for RA. Unfortunately, the result of the study in 4786 patients comparing MTX 15–20 mg/week or placebo over 2.3 years was negative: the HR for the study in 4786 patients comparing MTX 15–20 mg/week to the low CRP levels at baseline, 1.5 mg/L. For comparison, the mean CRP level at baseline in the canakinumab study (ref) was 4.2 mg/L and decreased 40% during the study.

Remarkably, serum levels of IL-1β and IL-6 also did not decrease in CIRT, which suggests that MTX in this population did not target these critical cytokines. However, in patients with inflammatory conditions, such as RA, the results can be different: Roubille et al showed a 28% reduction in cardiovascular events in MTX users.

The Colchicine Cardiovascular Outcomes Trial study, published in 2019, randomised 4745 patients with a recent myocardial infarction to colchicine 0.5 mg/day or placebo, in addition to their cardiovascular medication. The primary endpoint was a composite index of cardiovascular death, resuscitated cardiac arrest, myocardial infarction, stroke or urgent hospitalisation for angina leading to coronary revascularisation. This endpoint was met in 5.5% of colchicine-treated patients and in 7.7% of the placebo group (HR 0.77, 95% CI: 0.61 to 0.96, p=0.02). However, this difference was based on a 50% reduction in angina leading to revascularisation and 75% reduction in stroke, without significant reduction in the other three endpoints. Therefore, the results were criticised in that the benefit was modest and driven by the soft endpoint of angina for revascularisation and thus did not support routine use of colchicine without a better understanding of the absence of effect on myocardial infarct and death.

What about the side effects? Diarrhoea was found in similar proportions, 9.7% (colchicine) versus 8.9% (placebo), p=0.35, probably related to the low dosage of colchicine. Somewhat unexpectedly, pneumonia occurred more often in colchicine users (9.0% vs 5.2%, p=0.03). Another remarkable point is that statins were used in 94% of patients, but myalgias, regarded as a common side effect, occurred only slightly more frequently in colchicine users: 21.2% versus 15.8%.

Recently, Nidorf et al published a study (low dose colchicine (LoDoCo2)) that randomised 5522 patients to colchicine 0.5 mg/day or placebo. Only patients with chronic coronary disease were included, 84% had a previous acute coronary syndrome. After a median follow-up of 29 months, the primary endpoint (cardiovascular death, myocardial infarction, ischaemic stroke or ischaemic-driven coronary revascularisation) was met in 6.8% of the colchicine group and in 9.6% of the placebo group: (HR 0.69, 95% CI: 0.57 to 0.83, p=0.001). In addition, favourable (non-significant) trends were seen for cardiovascular death (20 in colchicine-treated patients vs 25 in placebo) but not for non-cardiovascular death (53 vs 35, respectively).

Very recently, in an interesting but relatively small Australian randomised controlled study (COPS) in 795 patients with an acute coronary syndrome, 24 cardiovascular events were observed in the colchicine group and 38 in the placebo group (p=0.09), although there was an increased risk in non-cardiovascular death in the colchicine group (5 vs 0, p=0.024). It is possible that the imbalance in non-cardiovascular death was related to chance, in the COPS trial 3/5 non-cardiovascular deaths occurred in patients who ceased colchicine early (<30 days) and died months later. In the LoDoCo2 trial, a favourable trend was seen for cardiovascular death in the colchicine group: as a consequence, the risk of non-cardiovascular death was higher in the placebo group. In meta-analyses, no significant increase in non-cardiovascular death was found. That is reassuring, but further research on this topic should be on the research agenda.

WHAT CAN WE LEARN FROM THESE TRIALS?

The favourable results for canakinumab and colchicine confirm (low-grade) inflammation as an independent risk factor for cardiovascular events and a new opportunity for treatment. The negative results in the MTX study do not detract from this, as the levels of CRP, IL-1β and IL-6 did not decrease during MTX treatment.

In addition, the large number of included patients yield important information on side effects: cancers, particularly non-basal cell skin cancers, occurred more often in the MTX group; the sample size of this study exceeds previous RCTs within the field of rheumatology with MTX. Remarkably, the occurrence of myalgias did not differ significantly between colchicine and placebo users. Whether or not colchicine leads to an increased risk of non-cardiovascular death needs to be elucidated.

The data on the favourable cardiovascular effects and safety of colchicine are convincing, and the drug costs are low. Moreover, all rheumatologists have experience in the long-term use with this drug and side effects are usually mild and rare, although colchicine must not be described in patients with advanced renal disease and might be limited by leucopenia and polyneuropathy. Perhaps the most burning question is: how to implement the findings of these studies? We have several recommendations:

First, we believe that cardiologists are not (yet) used to prescribe anti-inflammatory drugs for secondary prevention of cardiovascular events and may be somewhat reluctant to do that. Thus, our first-line action should be to...
initiate contact between the rheumatologist and the cardiologist and to discuss whether the additional use of an anti-inflammatory drug such as colchicine is an option in patients at high risk for secondary cardiovascular events.

Second, we also feel that national organisations of rheumatology should start forging bridges with national organisations of cardiology to help to implement the use of anti-inflammatory drugs for the secondary prevention of cardiovascular events in patients with atherosclerosis. The same applies to our larger organisations, such as EULAR, ACR and ILAR.

Third, the recent convincingly positive results lead to many follow-up questions on the research agenda: is the benefit seen with colchicine and canakinumab in secondary prevention also applicable in primary prevention? As rheumatologists, we would be inclining this first and foremost in patients with inflammatory rheumatological diseases.

Fourth, for the academic rheumatologist, these findings point to many important avenues for future research. Studies of these mechanisms have been boosted by the availability of successful treatments, and we anticipate that the demonstrated clinical benefit of IL-1 blockade will refine our understanding of the role of this cytokine in atherogenesis and that of future successful treatments in this arena.

In summary, we are convinced that the use of anti-inflammatory and immunomodulatory medications is now becoming a reality for the secondary prevention of cardiovascular events, with colchicine as the first drug in the clinic, but with the expectation that hopefully this is only the first in a future series of anti-inflammatory drugs. As rheumatologists, being experts on the use of these medications, we should embrace a new role in extending their potential benefits to millions of individuals.

Contributors WL initiated the manuscript and selected the studies on anti-inflammatory drugs and cardiovascular endpoints. MN delivered the first part on atherosclerosis as an inflammatory process and critically revised the manuscript. MB and RFV critically revised the manuscript and added valuable thoughts about the implementation. All authors approved the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests WL: received fees for lectures and advisory boards from Amgen, Eli Lilly, UCB, Pfizer, Galapagos and Curaphar; RFV: research support (institutional grants): BMS, GSK, Lilly and UCB; support for educational programs (institutional grants): Pfizer and Roche; consultancy, for which institutional and/or personal honoraria were received: AbbVie, AstraZeneca, Biogen, Biostech, Celgene, Galapagos, Gilead, Janssen, Pfizer, Sanofi, Servier and UCB and speaker, for which institutional and/or personal honoraria were received: AbbVie, Galapagos, Janssen, Pfizer and UCB. MN: consulting fees from AbbVie, Celgene, Celletrion, Eli Lilly, Janssen and Sanofi, speaker’s fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Roche and Sanofi and research funding from AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, MSD, Mundipharma, Novartis, Pfizer, Roche and Sanofi.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available in a public, open access repository.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs Willem Lems http://orcid.org/0000-0002-6885-3953
Maarten Boers http://orcid.org/0000-0002-6969-285X
Ronald F van Vollenhoven http://orcid.org/0000-0001-6438-8663

REFERENCES